Goals of antihypertensive treatment and planning of therapeutic trials

Alberto Zanchett

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The prevention of both cardiovascular events and organ damage or disease have to be considered to be different, but essential, goals of antihypertensive therapy. As the mechanisms that lead to organ damage and to events are, to a significant extent, different, it must be recognized that the achievement of the two goals has to be evaluated through trials using, separately or conjointly, different criteria. Thus far, randomized trials of antihypertensive therapy have almost exclusively measured mortality and morbidity data, and have provided information relevant to the prevention of cardiovascular events in those hypertensive patients in whom a relatively high rate of events is expected during the relatively short time span (3 to 6 years) of the trial, namely, those who have severe hypertension or who are elderly. However, in young or middle-aged patients with mild-to-moderate hypertension, for whom the goal of therapy would be to prevent or retard the development of vascular lesions to help these patients achieve their full life span, trials should be based on the measurement of organ damage rather than, or in addition to, the monitoring of events. The MIDAS trial has been the first in which two different modes of antihypertensive therapy have been tested for their capacity to influence the development of atherosclerosis in hypertension. It is likely that the results of this study will prompt many more therapeutic trials based on the quantitative assessment of organ damage in hypertension. Am J Hypertens 1994;7:13S–15S.

Original languageEnglish
Pages (from-to)13S-15S
JournalAmerican Journal of Hypertension
Volume7
Issue number7
DOIs
Publication statusPublished - 1994

Fingerprint

Antihypertensive Agents
Hypertension
Therapeutics
Blood Vessels
Atherosclerosis
Morbidity
Mortality

Keywords

  • Antihypertensive treatment
  • Cardiovascular damage
  • Cardiovascular events
  • Trial design

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Goals of antihypertensive treatment and planning of therapeutic trials. / Zanchett, Alberto.

In: American Journal of Hypertension, Vol. 7, No. 7, 1994, p. 13S-15S.

Research output: Contribution to journalArticle

@article{28a300e062104315ab5b9d99a72af903,
title = "Goals of antihypertensive treatment and planning of therapeutic trials",
abstract = "The prevention of both cardiovascular events and organ damage or disease have to be considered to be different, but essential, goals of antihypertensive therapy. As the mechanisms that lead to organ damage and to events are, to a significant extent, different, it must be recognized that the achievement of the two goals has to be evaluated through trials using, separately or conjointly, different criteria. Thus far, randomized trials of antihypertensive therapy have almost exclusively measured mortality and morbidity data, and have provided information relevant to the prevention of cardiovascular events in those hypertensive patients in whom a relatively high rate of events is expected during the relatively short time span (3 to 6 years) of the trial, namely, those who have severe hypertension or who are elderly. However, in young or middle-aged patients with mild-to-moderate hypertension, for whom the goal of therapy would be to prevent or retard the development of vascular lesions to help these patients achieve their full life span, trials should be based on the measurement of organ damage rather than, or in addition to, the monitoring of events. The MIDAS trial has been the first in which two different modes of antihypertensive therapy have been tested for their capacity to influence the development of atherosclerosis in hypertension. It is likely that the results of this study will prompt many more therapeutic trials based on the quantitative assessment of organ damage in hypertension. Am J Hypertens 1994;7:13S–15S.",
keywords = "Antihypertensive treatment, Cardiovascular damage, Cardiovascular events, Trial design",
author = "Alberto Zanchett",
year = "1994",
doi = "10.1093/ajh/7.7.13S",
language = "English",
volume = "7",
pages = "13S--15S",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Goals of antihypertensive treatment and planning of therapeutic trials

AU - Zanchett, Alberto

PY - 1994

Y1 - 1994

N2 - The prevention of both cardiovascular events and organ damage or disease have to be considered to be different, but essential, goals of antihypertensive therapy. As the mechanisms that lead to organ damage and to events are, to a significant extent, different, it must be recognized that the achievement of the two goals has to be evaluated through trials using, separately or conjointly, different criteria. Thus far, randomized trials of antihypertensive therapy have almost exclusively measured mortality and morbidity data, and have provided information relevant to the prevention of cardiovascular events in those hypertensive patients in whom a relatively high rate of events is expected during the relatively short time span (3 to 6 years) of the trial, namely, those who have severe hypertension or who are elderly. However, in young or middle-aged patients with mild-to-moderate hypertension, for whom the goal of therapy would be to prevent or retard the development of vascular lesions to help these patients achieve their full life span, trials should be based on the measurement of organ damage rather than, or in addition to, the monitoring of events. The MIDAS trial has been the first in which two different modes of antihypertensive therapy have been tested for their capacity to influence the development of atherosclerosis in hypertension. It is likely that the results of this study will prompt many more therapeutic trials based on the quantitative assessment of organ damage in hypertension. Am J Hypertens 1994;7:13S–15S.

AB - The prevention of both cardiovascular events and organ damage or disease have to be considered to be different, but essential, goals of antihypertensive therapy. As the mechanisms that lead to organ damage and to events are, to a significant extent, different, it must be recognized that the achievement of the two goals has to be evaluated through trials using, separately or conjointly, different criteria. Thus far, randomized trials of antihypertensive therapy have almost exclusively measured mortality and morbidity data, and have provided information relevant to the prevention of cardiovascular events in those hypertensive patients in whom a relatively high rate of events is expected during the relatively short time span (3 to 6 years) of the trial, namely, those who have severe hypertension or who are elderly. However, in young or middle-aged patients with mild-to-moderate hypertension, for whom the goal of therapy would be to prevent or retard the development of vascular lesions to help these patients achieve their full life span, trials should be based on the measurement of organ damage rather than, or in addition to, the monitoring of events. The MIDAS trial has been the first in which two different modes of antihypertensive therapy have been tested for their capacity to influence the development of atherosclerosis in hypertension. It is likely that the results of this study will prompt many more therapeutic trials based on the quantitative assessment of organ damage in hypertension. Am J Hypertens 1994;7:13S–15S.

KW - Antihypertensive treatment

KW - Cardiovascular damage

KW - Cardiovascular events

KW - Trial design

UR - http://www.scopus.com/inward/record.url?scp=0028108867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028108867&partnerID=8YFLogxK

U2 - 10.1093/ajh/7.7.13S

DO - 10.1093/ajh/7.7.13S

M3 - Article

VL - 7

SP - 13S-15S

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 7

ER -